Return on investment of internet delivered exposure therapy for irritable bowel syndrome: a randomized controlled trial

Table 4 Estimates from bootstrapped mixed models analyses of GSRS-IBS and costs

Estimate	B	s.e	95% CI	B	s.e	95% CI
Intercept	47.52	0.98	[45.82, 49.23]	9804	867	[8181, 11557]
Group	− 1.39	1.39	[− 3.76, 0.92]	− 980	1233	[− 3451, 1448]
T1	− 9.09	0.84	[− 10.74, − 7.54]	66	754	[− 1085, 1236]
T1*Group	− 3.87	1.19	[− 6.12, − 1.64]	− 467	1072	[− 2340, 1411]
T2	− 0.47	0.87	[− 1.96, 1.07]	502	793	[− 1107, 2131]
T2*Group	− 0.09	1.23	[− 2.31, 2.13]	− 729	1118	[− 2979, 1473]
T1Group + T2Group	− 3.96	1.23	[− 6.62, − 1.32]	− 1196	1110	[− 3550, 1256]

95% CI: Bootstrapped 95% confidence interval. GSRS-IBS: Gastrointestinal Symptom Rating Scale—IBS version
The estimates are from bootstrapped piecewise mixed models regression analyses of GSRS-IBS scores and total costs, including intervention costs. The T1 and T2 variables denote the time from pre-treatment to post-treatment and from post-treatment to 6-month follow-up, respectively. The T1 and T2 interaction effects with the Group variable denote the differential developments over time between the study groups during these two time periods. The summed interaction effect is the cumulative difference in change between pre-treatment to 6-month follow-up

ISSN: 1471-230X